Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$39.16 USD

39.16
2,512,037

+0.26 (0.67%)

Updated Jul 12, 2024 03:59 PM ET

After-Market: $39.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

    J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?

    The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

      Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III

      Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.

        Tracey Ryniec headshot

        What All Investors Should Know about Trade Deficits and Recessions

        What's the trade deficit really about? And what are the key signals that may alert investors to an upcoming recession?

          Merck's Keytruda Offers Survival Benefit in Lung Cancer Study

          Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.

            Indrajit Bandyopadhyay headshot

            4 Drug/Biotech Stocks to Buy Ahead of World Health Day

            Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.

              Novartis Announces Data on Cardiovascular Drug Entresto

              Novartis AG (NVS) announces encouraging results from the PARADIGM-HF trial on cardiovascular drug Entresto in JAMA Cardiology wherein it was observed Entresto significantly improved seven out of 10 types of physical and social activities at eight months.

                Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study

                A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.

                  GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?

                  As GlaxoSmithKline (GSK) starts a strategic review of Horlicks and other smaller nutrition products, a number of companies in the food & beverage industry are waiting to scoop it up.

                    Puma's Shares Fall This Year Post a Solid 2017: Here's Why

                    Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.

                      Company News For Mar 28, 2018

                      Companies in the news are: RHT,MKC,INFO,GSK,NVS

                        Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV

                        Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.

                          Kinjel Shah headshot

                          4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End

                          The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying

                            Pfizer's Chantix Fails in Phase IV Study in Young Smokers

                            Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.

                              Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod

                              Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.

                                GlaxoSmithKline Initiates Phase III Combo Study on Benlysta

                                GlaxoSmithKline (GSK) initiates a phase III study evaluating Benlysta in combination with Rituxanin adult patients with systemic lupus erythematosus.

                                  Pfizer's Xtandi Label Expansion Filing Gets Priority Review

                                  FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

                                    Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus

                                    Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.

                                      J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status

                                      The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.

                                        Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

                                        Let's see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

                                          Merck's Keytruda Gets Priority Review for Cervical Cancer

                                          Merck's (MRK) sBLA for Keytruda to expand its label for the treatment of advanced cervical cancer gets acceptance for priority review by the FDA.

                                            Gilead Announces Positive Data on New HIV Therapy Biktarvy

                                            Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.

                                              Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss

                                              Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.

                                                5 Reasons Why Pfizer (PFE) Could be a Great Pick in 2018

                                                Pfizer's (PFE) outperformance is backed by decent quarterly results, positive news flow and regulatory updates.

                                                  Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid

                                                  Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.